Forwarded from 🇾🇪سفراء الإنسانية🥀GROUP 1 (بروفيسوره😎)
سلايدات الCVS
معمل باثو
معمل باثو
GROUP 3 Third year
Patho. Lab. Review-reduced.pdf
سلايدات معمل الباثو
General & Systemic
General & Systemic
مساااكم 🌺
ال cases تبع اليوم في معمل الفارما
المطلوب تحلوهن جروب مكون من ٥ اشخاص
والمعمل الجاي تسلموهن 🤗🤗
ال cases تبع اليوم في معمل الفارما
المطلوب تحلوهن جروب مكون من ٥ اشخاص
والمعمل الجاي تسلموهن 🤗🤗
Forwarded from عبد السلام عقلان
✍ FDA Approves First Vaccine for Dengue, With Restrictions
May 02, 2019
👉The US Food and Drug Administration (FDA) has approved the first vaccine to prevent dengue disease caused by all dengue virus serotypes (1, 2, 3, and 4) for people aged 9 through 16 years who have previously had laboratory-confirmed dengue infection and who live in endemic areas.
👉The vaccine, Dengvaxia (Sanofi Pasteur), is a live, attenuated vaccine given in three injections. The initial dose is followed by two additional injections 6 and 12 months later.
👉"Dengue disease is the most common mosquito-borne viral disease in the world and global incidence has increased in recent decades. While there is no cure for dengue disease, [this] approval is an important step toward helping to reduce the impact of this virus in endemic regions of the United States,"
👉Dengue is endemic in the US territories of American Samoa, Guam, Puerto Rico, and the US Virgin Islands.
👉A first dengue infection usually causes no symptoms or is a mild illness that resembles the flu or another viral infection. However, a subsequent infection can lead to severe dengue and may result in dengue hemorrhagic fever (DHF), which can be fatal. Most cases of severe dengue are associated with a second dengue virus infection. Because no drugs have been specifically approved for the treatment of dengue disease, care is limited to the management of symptoms.
👉"Infection by one type of dengue virus usually provides immunity against that specific serotype, but a subsequent infection by any of the other three serotypes of the virus increases the risk of developing severe dengue disease, which may lead to hospitalization or even death,"
👉 "As the second infection with dengue is often much more severe than the first, the FDA's approval of this vaccine will help protect people previously infected with dengue virus from subsequent development of dengue disease."
👉The vaccine was roughly 76% effective in preventing symptomatic, laboratory-confirmed dengue disease in individuals aged 9 to 16 years who had previously had laboratory-confirmed dengue disease.
👉The most commonly reported side effects with Dengvaxia are headache, muscle pain, joint pain, fatigue, injection site pain, and low-grade fever. The frequency of side effects was similar among patients who received Dengvaxia and those who received placebo. Side effects tended to decrease after each subsequent dose of the vaccine.
👉Dengvaxia is not approved for people not previously infected by any dengue virus serotype or for patients whose status regarding previous infection is unknown. "This is because in people who have not been infected with dengue virus, Dengvaxia appears to act like a first dengue infection — without actually infecting the person with wild-type dengue virus — such that a subsequent infection can result in severe dengue disease," the FDA says.
👉 the FDA advises healthcare professionals to evaluate individuals for prior dengue infection to avoid vaccinating persons who have not been previously infected by dengue virus. Confirmation of previous infection can be established through a medical record of the patient's having previously had a laboratory-confirmed dengue infection or through serologic testing prior to vaccination.
👉It is estimated that one third of the world's population live in areas at risk for infection by dengue virus. Each year, an estimated 400 million dengue virus infections occur globally, according to the US Centers for Disease Control and Prevention. Of these, roughly 500,000 cases develop into DHF, which contributes to about 20,000 deaths, primarily among children.
👉The FDA granted the Dengvaxia application priority review and a tropical disease priority review voucher under a program intended to encourage development of new drugs for the prevention and treatment of certain tropical diseases.
👉Dengvaxia is approved in 19 countries and the European Union.
May 02, 2019
👉The US Food and Drug Administration (FDA) has approved the first vaccine to prevent dengue disease caused by all dengue virus serotypes (1, 2, 3, and 4) for people aged 9 through 16 years who have previously had laboratory-confirmed dengue infection and who live in endemic areas.
👉The vaccine, Dengvaxia (Sanofi Pasteur), is a live, attenuated vaccine given in three injections. The initial dose is followed by two additional injections 6 and 12 months later.
👉"Dengue disease is the most common mosquito-borne viral disease in the world and global incidence has increased in recent decades. While there is no cure for dengue disease, [this] approval is an important step toward helping to reduce the impact of this virus in endemic regions of the United States,"
👉Dengue is endemic in the US territories of American Samoa, Guam, Puerto Rico, and the US Virgin Islands.
👉A first dengue infection usually causes no symptoms or is a mild illness that resembles the flu or another viral infection. However, a subsequent infection can lead to severe dengue and may result in dengue hemorrhagic fever (DHF), which can be fatal. Most cases of severe dengue are associated with a second dengue virus infection. Because no drugs have been specifically approved for the treatment of dengue disease, care is limited to the management of symptoms.
👉"Infection by one type of dengue virus usually provides immunity against that specific serotype, but a subsequent infection by any of the other three serotypes of the virus increases the risk of developing severe dengue disease, which may lead to hospitalization or even death,"
👉 "As the second infection with dengue is often much more severe than the first, the FDA's approval of this vaccine will help protect people previously infected with dengue virus from subsequent development of dengue disease."
👉The vaccine was roughly 76% effective in preventing symptomatic, laboratory-confirmed dengue disease in individuals aged 9 to 16 years who had previously had laboratory-confirmed dengue disease.
👉The most commonly reported side effects with Dengvaxia are headache, muscle pain, joint pain, fatigue, injection site pain, and low-grade fever. The frequency of side effects was similar among patients who received Dengvaxia and those who received placebo. Side effects tended to decrease after each subsequent dose of the vaccine.
👉Dengvaxia is not approved for people not previously infected by any dengue virus serotype or for patients whose status regarding previous infection is unknown. "This is because in people who have not been infected with dengue virus, Dengvaxia appears to act like a first dengue infection — without actually infecting the person with wild-type dengue virus — such that a subsequent infection can result in severe dengue disease," the FDA says.
👉 the FDA advises healthcare professionals to evaluate individuals for prior dengue infection to avoid vaccinating persons who have not been previously infected by dengue virus. Confirmation of previous infection can be established through a medical record of the patient's having previously had a laboratory-confirmed dengue infection or through serologic testing prior to vaccination.
👉It is estimated that one third of the world's population live in areas at risk for infection by dengue virus. Each year, an estimated 400 million dengue virus infections occur globally, according to the US Centers for Disease Control and Prevention. Of these, roughly 500,000 cases develop into DHF, which contributes to about 20,000 deaths, primarily among children.
👉The FDA granted the Dengvaxia application priority review and a tropical disease priority review voucher under a program intended to encourage development of new drugs for the prevention and treatment of certain tropical diseases.
👉Dengvaxia is approved in 19 countries and the European Union.
Forwarded from عبد السلام عقلان
👉 Istradefylline
✍ The US Food and Drug Administration (FDA) has approved istradefylline (Nourianz, Kyowa Kirin) tablets as add-on treatment to levodopa/carbidopa in adults with Parkinson's disease (PD) experiencing "off" episodes.
✍ Istradefylline is a selective adenosine A2A receptor antagonist.
✍ The most common adverse reactions observed in patients taking istradefylline were dyskinesia, dizziness, constipation, nausea, hallucination, and insomnia. Patients should be monitored for development of dyskinesia or exacerbation of existing dyskinesia. If hallucinations, psychotic behavior, or impulsive/compulsive behavior occurs, consider reducing the dose or stopping the drug, the FDA advises.
✍ Use of istradefylline in pregnancy is not recommended and women of childbearing potential should be advised to use contraception during treatment.
✍ According to the National Institutes of Health, PD is the second most common neurodegenerative disorder in the United States after Alzheimer's disease. An estimated 50,000 Americans are diagnosed with PD each year, and about 1 million Americans have the condition
✍ The US Food and Drug Administration (FDA) has approved istradefylline (Nourianz, Kyowa Kirin) tablets as add-on treatment to levodopa/carbidopa in adults with Parkinson's disease (PD) experiencing "off" episodes.
✍ Istradefylline is a selective adenosine A2A receptor antagonist.
✍ The most common adverse reactions observed in patients taking istradefylline were dyskinesia, dizziness, constipation, nausea, hallucination, and insomnia. Patients should be monitored for development of dyskinesia or exacerbation of existing dyskinesia. If hallucinations, psychotic behavior, or impulsive/compulsive behavior occurs, consider reducing the dose or stopping the drug, the FDA advises.
✍ Use of istradefylline in pregnancy is not recommended and women of childbearing potential should be advised to use contraception during treatment.
✍ According to the National Institutes of Health, PD is the second most common neurodegenerative disorder in the United States after Alzheimer's disease. An estimated 50,000 Americans are diagnosed with PD each year, and about 1 million Americans have the condition
🚨 حــقــيــقــة تــحــذيـر مــنــظـمــة FDA مــن دواء الــ (Ranitidine) 🚨
كالعادة يحب الكثيرون نقل الأخبار 💥المولعة💥 حتى لو لم تكن دقيقة 😅
♨️ مــا هــي الـمـشـكــلـة الــحــقــيــقــيــة ؟؟
عثرت منظمة الــ FDA على "كميات منخفضة" من مادة يشتبه في كونها مسببة للسرطان تسمى (NDMA) .. مخلوطة مع المادة الفعالة (Ranitidine) !!
_____________
💦 مــا هــو الـمـطـلــوب حــالــيــاً ؟؟
1️⃣ المطلوب من المنظمات الصحية -مثل FDA- هو مواصلة الأبحاث بــهــدفــيــن هما :
🔹 تقييم درجة الخطر الذي تشكله "الكميات المنخفضة" من مادة (NDMA) على البشر .. وهل هي فعلا تشكل خطراً حقيقياً عليهم أو لا ؟؟
🔹 محاولة إيجاد طريقة لتصنيع الـ (Ranitidine) تضمن عدم تلوثه بهذه المادة ..
2️⃣ المطلوب من المرضى الذين يتناولون الــ (Ranitidine) :
بحسب الدراسات الحالية .. ليس مطلوبا إيقاف الدواء و لا تبديله بدواء آخر (إلا من أراد أن يفعل ذلك بشكل اختياري) ..
#Ph_Waleed_Al_Sibakhi
لمن أراد التأكد هذا الرابط
https://www.fda.gov/news-events/press-announcements/statement-alerting-patients-and-health-care-professionals-ndma-found-samples-ranitidine?fbclid=IwAR2An9U1fu0zGjv95pIXFVIVuRbrfggw_tgvT7g0N74DGu7z0wQ1LgJu6ew
كالعادة يحب الكثيرون نقل الأخبار 💥المولعة💥 حتى لو لم تكن دقيقة 😅
♨️ مــا هــي الـمـشـكــلـة الــحــقــيــقــيــة ؟؟
عثرت منظمة الــ FDA على "كميات منخفضة" من مادة يشتبه في كونها مسببة للسرطان تسمى (NDMA) .. مخلوطة مع المادة الفعالة (Ranitidine) !!
_____________
💦 مــا هــو الـمـطـلــوب حــالــيــاً ؟؟
1️⃣ المطلوب من المنظمات الصحية -مثل FDA- هو مواصلة الأبحاث بــهــدفــيــن هما :
🔹 تقييم درجة الخطر الذي تشكله "الكميات المنخفضة" من مادة (NDMA) على البشر .. وهل هي فعلا تشكل خطراً حقيقياً عليهم أو لا ؟؟
🔹 محاولة إيجاد طريقة لتصنيع الـ (Ranitidine) تضمن عدم تلوثه بهذه المادة ..
2️⃣ المطلوب من المرضى الذين يتناولون الــ (Ranitidine) :
بحسب الدراسات الحالية .. ليس مطلوبا إيقاف الدواء و لا تبديله بدواء آخر (إلا من أراد أن يفعل ذلك بشكل اختياري) ..
#Ph_Waleed_Al_Sibakhi
لمن أراد التأكد هذا الرابط
https://www.fda.gov/news-events/press-announcements/statement-alerting-patients-and-health-care-professionals-ndma-found-samples-ranitidine?fbclid=IwAR2An9U1fu0zGjv95pIXFVIVuRbrfggw_tgvT7g0N74DGu7z0wQ1LgJu6ew
U.S. Food and Drug Administration
Statement alerting patients and health care professionals of NDMA found in samples of ranitidine
FDA alerts of NDMA found in some raniditine medicines